Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note released on Wednesday. The firm issued a sell rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday.

Can-Fite BioPharma Trading Down 2.4 %

Shares of NYSE CANF opened at $1.20 on Wednesday. The stock has a market capitalization of $4.25 million, a price-to-earnings ratio of -0.67 and a beta of 1.37. Can-Fite BioPharma has a 12-month low of $1.18 and a 12-month high of $4.69. The firm’s 50-day moving average price is $1.55 and its 200-day moving average price is $1.76.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,880 shares of the company’s stock after acquiring an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.